Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 25;9(6):1366-1369.
doi: 10.1182/bloodadvances.2024014689.

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Matthew J Maurer  1 , Susan K Parsons  2 , Jenica N Upshaw  2 , Angie Mae Rodday  2 , Raphael Mwangi  1 , Sára Rossetti  3 , Jonathan W Friedberg  4 , Andrea Gallamini  5 , Massimo Federico  6 , Eliza Hawkes  7 , David Hodgson  8 , Peter Johnson  9 , Brian K Link  10 , Eric Mou  10 , Kerry J Savage  11 , Pier Luigi Zinzani  12 , Andrew M Evens  13
Affiliations

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Matthew J Maurer et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.K.P. reports consulting or advisory role with Seattle Genetics. J.W.F. is the Editor-in-Chief of Journal of Clinical Oncology, and the journal policy recused the author from having any role in the peer review of this manuscript; reports research funding from Enterome (institutional); and reports patents, royalties, and other intellectual property pertaining to bone marrow microenvironment signals (institutional). A.G. reports honoraria and consulting/advisory role with Takeda. E.H. reports consulting or advisory role with Merck Sharpe & Dohme (institutional), Roche/Genentech (institutional), AstraZeneca, Gilead Sciences (institutional), Bristol Myers Squibb (institutional), Servier, Novartis (institutional), BeiGene (institutional), Link Healthcare (institutional), and Antengene (institutional); speakers' bureau fees from Roche/Genentech, Regeneron, and AbbVie (institutional); and research funding from AstraZeneca (institutional), Celgene (institutional), Merck KGaA (institutional), Janssen-Cilag (institutional), Gilead Sciences (institutional), Mundipharma (institutional), Bristol Myers Squibb (institutional), and Roche/Genentech (institutional). P.J. reports honoraria from Genmab, Epizyme, and Incyte; consulting or advisory role with Epizyme; and patents, royalties, and other intellectual property regarding combined use of Fc gamma RIIb (CD32b) and CD20-specific antibodies (WO Patent, PCT/GB2011/051572; EU11760819.0). B.K.L. reports consulting or advisory role with Genentech/Roche, MEI Pharma, and Amgen; and research funding from Pharmacyclics/Janssen (institutional), Genentech/AbbVie (institutional), and Genmab (institutional). K.J.S. reports honoraria from Seattle Genetics, Roche, and Abbvie,; consulting or advisory role with Seattle Genetics, Roche and Abbvie; research funding from Bristol Myers Squibb, Seattle Genetics (institutional), Viracta (institutional), and Merck (institutional); and other relationship, including Data and Safety Monitoring Committee role, and uncompensated relationships with Regeneron. P.L.Z. reports consulting or advisory role with Celltrion, Gilead Sciences, Janssen-Cilag, Bristol Myers Squibb, Servier, Sandoz, MSD, Roche, EUSA Pharma, Kyowa Hakko Kirin, Takeda, Secura BIO, TG Therapeutics, Novartis, ADC Therapeutics, Incyte, and BeiGene; and speakers' bureau fees from MSD, EUSA Pharma, and Novartis. M.J.M. reports employment and stock/other ownership interests in Exact Sciences (immediate family member); consulting or advisory role with Bristol Myers Squibb (institutional); and research funding from Bristol Myers Squibb (institutional), Roche/Genentech (institutional), and Genmab (institutional). A.M.E. reports honoraria from Pfizer, Pharmacyclics, Research to Practice, Epizyme, Novartis, MorphoSys, Incyte, Targeted Oncology, AbbVie, Takeda, Patient Power, PER, OncLive Clinical Congress Consultants, HUTCHMED, Incyte, MorphoSys, and Daiichi Sankyo/AstraZeneca; consulting or advisory role with Pfizer, Novartis, Pharmacyclics, Incyte, Epizyme, MorphoSys, AbbVie, Incyte, and MorphoSys; and speakers' bureau fees from Research to Practice. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Online tool and alternative risk group analyses. (A) Screenshot of the A-HIPI risk group online tool. Users may select individualized percentile cutoffs for defining low- and high-risk disease. The application will provide dynamic outcomes based on the user-defined individualized risk groups. See interactive app at https://rtools.mayo.edu/holistic_ahipi/. (B) Risk groups based on deviation from average patient or clinical thresholds. The right-skewed distribution of A-HIPI risk scores greatly limited the applicability of these approaches. The standard-risk approach of the average patient was limited by the asymmetric distribution of patients because the majority of patients were considered average risk, and only ∼20% of patients were considered increased or high risk (approach 1). Proposed cutoffs based on clinical thresholds of PFS5 <70 and PFS5 >90 only identified 15% and <1% of the population, respectively (approach 2). 5y, 5-year; A-HIPI, advanced-stage Hodgkin lymphoma international prognostic index; PFS5, 5-year progression-free survival.
See this image and copyright information in PMC

References

    1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339(21):1506–1514. - PubMed
    1. International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987–994. - PubMed
    1. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265. - PubMed
    1. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080. - PMC - PubMed
    1. Hodgkin Lymphoma International Study for Individual Care. HoLISTIC Consortium www.hodgkinconsortium.com